Effect of longacting somatostatin analogue on kidney and cyst growth in autosomal dominant polycystic kidney disease (ALADIN): a randomised, placebo-controlled, multicentre trial
暂无分享,去创建一个
Luca Antiga | Andrea Remuzzi | Paolo Brambilla | Giuseppe Remuzzi | Luca Cancian | Nadia Rubis | Piero Ruggenenti | Massimo Imbriaco | Anna Caroli | Norberto Perico | L. Antiga | N. Perico | G. Remuzzi | A. Remuzzi | P. Brambilla | F. Gaspari | P. Ruggenenti | A. Caroli | N. Rubis | S. Prandini | A. Pisani | A. Perna | B. Visciano | M. Imbriaco | P. Messa | R. Cerutti | M. Dugo | L. Cancian | E. Buongiorno | A. Pascalis | Fabiola Carrara | Antonio Pisani | Piergiorgio Messa | Roberta Cerutti | Annalisa Perna | Bianca Visciano | Mauro Dugo | Erasmo Buongiorno | Antonio De Pascalis | Flavio Gaspari | Fabiola Carrara | Silvia Prandini | Silvia Prandini
[1] J. Stockman. A 12-Month Phase 3 Study of Pasireotide in Cushing's Disease , 2013 .
[2] Eiji Higashihara,et al. Tolvaptan in patients with autosomal dominant polycystic kidney disease. , 2012, The New England journal of medicine.
[3] N. LaRusso,et al. Somatostatin analog therapy for severe polycystic liver disease: results after 2 years. , 2012, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[4] R. Miniero,et al. Effect of Recombinant Human Growth Hormone (rhGH) on Hemoglobin Concentration in Children With Idiopathic Growth Hormone Deficiency-related Anemia , 2012, Journal of pediatric hematology/oncology.
[5] V. Torri,et al. Meta-Analysis on the Effects of Octreotide on Tumor Mass in Acromegaly , 2012, PloS one.
[6] N. Perico,et al. Measuring and Estimating GFR and Treatment Effect in ADPKD Patients: Results and Implications of a Longitudinal Cohort Study , 2012, PloS one.
[7] J. Stockman,et al. Everolimus in Patients with Autosomal Dominant Polycystic Kidney Disease , 2012 .
[8] R. Schrier,et al. Glomerular hyperfiltration and renal progression in children with autosomal dominant polycystic kidney disease. , 2011, Clinical journal of the American Society of Nephrology : CJASN.
[9] J. Glockner,et al. Short-term effects of tolvaptan on renal function and volume in patients with autosomal dominant polycystic kidney disease. , 2011, Kidney international.
[10] L. Ruilope,et al. Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. , 2011, The New England journal of medicine.
[11] Oliver Senn,et al. Sirolimus and kidney growth in autosomal dominant polycystic kidney disease. , 2010, The New England journal of medicine.
[12] James Glockner,et al. Randomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney and liver disease. , 2010, Journal of the American Society of Nephrology : JASN.
[13] L. Antiga,et al. Reducing polycystic liver volume in ADPKD: effects of somatostatin analogue octreotide. , 2010, Clinical journal of the American Society of Nephrology : CJASN.
[14] D. Moher,et al. CONSORT 2010 Statement: updated guidelines for reporting parallel group randomized trials , 2010, Obstetrics and gynecology.
[15] D. Moher,et al. CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials , 2010, Journal of clinical epidemiology.
[16] M. V. van Oijen,et al. Lanreotide reduces the volume of polycystic liver: a randomized, double-blind, placebo-controlled trial. , 2009, Gastroenterology.
[17] J. Grantham,et al. Clinical practice. Autosomal dominant polycystic kidney disease. , 2008, The New England journal of medicine.
[18] N. LaRusso,et al. Octreotide inhibits hepatic cystogenesis in a rodent model of polycystic liver disease by reducing cholangiocyte adenosine 3',5'-cyclic monophosphate. , 2007, Gastroenterology.
[19] A. Chapman,et al. Volume progression in autosomal dominant polycystic kidney disease: the major factor determining clinical outcomes. , 2005, Clinical journal of the American Society of Nephrology : CJASN.
[20] L. Antiga,et al. Safety and efficacy of long-acting somatostatin treatment in autosomal-dominant polycystic kidney disease. , 2005, Kidney international.
[21] J. Grantham,et al. Lillian Jean Kaplan International Prize for advancement in the understanding of polycystic kidney disease. Understanding polycystic kidney disease: a systems biology approach. , 2003, Kidney international.
[22] Vincent H Gattone,et al. Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist , 2003, Nature Medicine.
[23] Paul A Thompson,et al. Renal structure in early autosomal-dominant polycystic kidney disease (ADPKD): The Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP) cohort. , 2003, Kidney international.
[24] F. Petraglia,et al. Administration of somatostatin analogue reduces uterine and myoma volume in women with uterine leiomyomata. , 2001, Fertility and sterility.
[25] G. Remuzzi,et al. In chronic nephropathies prolonged ACE inhibition can induce remission: dynamics of time-dependent changes in GFR. Investigators of the GISEN Group. Gruppo Italiano Studi Epidemiologici in Nefrologia. , 1999, Journal of the American Society of Nephrology : JASN.
[26] D. Wallace,et al. Chloride and fluid secretion in polycystic kidney disease. , 1998, Journal of the American Society of Nephrology : JASN.
[27] J. Grantham,et al. Mechanisms of progression in autosomal dominant polycystic kidney disease. , 1997, Kidney international. Supplement.
[28] J. Edwardson,et al. Somatostatin receptors in Neuro2A neuroblastoma cells: ligand internalization , 1997, British journal of pharmacology.
[29] N. Perico,et al. Plasma clearance of nonradioactive iohexol as a measure of glomerular filtration rate. , 1995, Journal of the American Society of Nephrology : JASN.
[30] R. G. Walker,et al. Evaluation of ultrasonographic diagnostic criteria for autosomal dominant polycystic kidney disease 1 , 1994, The Lancet.
[31] U. Studer,et al. Human kidney as target for somatostatin: high affinity receptors in tubules and vasa recta. , 1993, The Journal of clinical endocrinology and metabolism.
[32] W. Jiménez,et al. Effects of somatostatin on renal function in cirrhosis. , 1992, Gastroenterology.
[33] C. Sullivan,et al. Effects of long term octreotide on gall stone formation and gall bladder function. , 1992, BMJ.
[34] T. M. Hayes,et al. Renal response to intravenous somatostatin in insulin-dependent diabetic patients and normal subjects. , 1987, The Journal of clinical endocrinology and metabolism.
[35] L. Travis,et al. Somatostatin limits rise in glomerular filtration rate after a protein meal. , 1987, The Journal of pediatrics.
[36] B. Brenner,et al. Control of glomerular hypertension limits glomerular injury in rats with reduced renal mass. , 1985, The Journal of clinical investigation.